Table 2.
Analysis of OAB-q SF scores and changes from baseline to 12 weeks (mean ± SD)
| Item | Tolterodine (n = 30) | Intravaginal Estradiol (n = 28) | t/F | p |
|---|---|---|---|---|
| Baseline | ||||
| OAB-q SF score | 65.48 ± 15.37 | 61.61 ± 20.04 | 19.375 | 0.421 |
| UI episodes | 10.42 ± 11.64 | 16.21 ± 10.54 | 4.594 | 0.554 |
| 12-week Follow-up | ||||
| OAB-q SF score | 46.71 ± 23.42* | 45.44 ± 21.01* | 4.058 | 0.815 |
| p | 0.025 | 0.028 | ||
| t/F | 5.982 | 7.531 | ||
| UI episodes | -1.27 ± 8.34# | -1.64 ± 7.22 | 7.251 | 0.854 |
| p | < 0.014 | 0.267 | ||
| t/F | 3.597 | 6.914 | ||
OAB-q SF, Overactive Bladder questionnaire short form; UI, urinary incontinence.
*
Compared to the 12-week follow-up OAB-q score within-group;
#
Compared to the 12-week follow-up UI episodes within-group.
All reported P values are paired t test P values.